Unknown

Dataset Information

0

Discovery of Nitro-azolo[1,5-a]pyrimidines with Anti-Inflammatory and Protective Activity against LPS-Induced Acute Lung Injury.


ABSTRACT: Acute lung injury remains a challenging clinical condition, necessitating the development of novel, safe and efficient treatments. The prevention of macrophage M1-polarization is a viable venue to tackle excessive inflammation. We performed a phenotypic screening campaign to identify azolopyrimidine compounds that effectively inhibit LPS-induced NO synthesis and interleukin 6 (IL-6) secretion. We identified lead compound 9g that inhibits IL-6 secretion with IC50 of 3.72 µM without apparent cytotoxicity and with minimal suppression of macrophage phagocytosis in contrast to dexamethasone. In a mouse model of LPS-induced acute lung injury, 30 mg/kg i.p. 9g ameliorated anxiety-like behavior, inhibited IL-6 release, and limited neutrophil infiltration and pulmonary edema. A histological study confirmed the protective activity of 9g. Treatment with compound 9g prevented the migration of CD68+ macrophages and the incidence of hemorrhage. Hence, we have identified a promising pharmacological approach for the treatment of acute lung injury that may hold promise for the development of novel drugs against cytokine-mediated complications of bacterial and viral infections.

SUBMITTER: Spasov A 

PROVIDER: S-EPMC9146423 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of Nitro-azolo[1,5-<i>a</i>]pyrimidines with Anti-Inflammatory and Protective Activity against LPS-Induced Acute Lung Injury.

Spasov Alexander A   Kosolapov Vadim V   Babkov Denis D   Klochkov Vladlen V   Sokolova Elena E   Miroshnikov Mikhail M   Borisov Alexander A   Velikorodnaya Yulia Y   Smirnov Alexey A   Savateev Konstantin K   Fedotov Victor V   Kotovskaya Svetlana S   Rusinov Vladimir V  

Pharmaceuticals (Basel, Switzerland) 20220427 5


Acute lung injury remains a challenging clinical condition, necessitating the development of novel, safe and efficient treatments. The prevention of macrophage M1-polarization is a viable venue to tackle excessive inflammation. We performed a phenotypic screening campaign to identify azolopyrimidine compounds that effectively inhibit LPS-induced NO synthesis and interleukin 6 (IL-6) secretion. We identified lead compound <b>9g</b> that inhibits IL-6 secretion with IC<sub>50</sub> of 3.72 µM with  ...[more]

Similar Datasets

| S-EPMC8746358 | biostudies-literature
| S-EPMC10054722 | biostudies-literature
| S-EPMC9863002 | biostudies-literature
| S-EPMC4846832 | biostudies-literature
| S-EPMC7981185 | biostudies-literature
| S-EPMC7391858 | biostudies-literature
| S-EPMC6180195 | biostudies-literature
| S-EPMC6218249 | biostudies-literature
| S-EPMC11376203 | biostudies-literature
| S-EPMC6394845 | biostudies-literature